

# SEER Inquiry System - Report

Produced: 05/09/2024 8:26 AM

## Question 20230069

### References:

#1: 2023 SEER Manual, 214-216. Immunotherapy

#2: SEER\*Rx

### Question:

First Course Treatment/Immunotherapy--Colon: Is infliximab cancer directed treatment? See Discussion.

### Discussion:

While SEER\*Rx does indicate infliximab should be coded as biological response modifier (BRM)/Immunotherapy, the manufacturer website for this medication indicates it is given for: Crohn's disease, ulcerative colitis, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. In addition, SEER\*Rx does not indicate which primary sites this treatment may be given for. If it is indeed cancer directed treatment, can the typical primary sites be added for clarity?

Case example: Patient is diagnosed with colorectal cancer and also has an existing diagnosis of Crohn's disease; received surgery and FOLFOX6, as well as infliximab. There was no statement of what disease the infliximab was given to treat.

### Answer:

infliximab is not cancer-directed treatment. This drug was last updated by the FDA 2/22/2023 with additional information on its approval to treat non-malignant neoplasms. To date, the FDA has not approved it for use in colon cancer. This drug was initially developed to treat colon cancer; however, found to be ineffective treating cancer.

### Cancer Site Category:

Colon

### Data Item Category:

First course treatment, Immunotherapy

### Other Category:

N/A

### Year:

2023